MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

Romero, A.; Serna, R.; Nadal, E.; Larriba, J.L. Glez; Martínez-Martí, A.; Bernabé, R.; Bosch-Barrera, J.; Fernandez, Alexander; Calvo, V.; Insa, A.; Ponce, S.; Reguart, N.; Castro, J. De; Massutí, B.; Palmero, R.; Rosa, C. Aguado de la; Mosquera, J.; Cobo, M.; Aguilar, Andy; Vivanco, Guillermo López; Camps, C.; Trancho, Florentino Hernando; Castro, R. López; Moran, T.; Barneto, I.; Rodríguez-Abreu, D.; Cruz, A.; Provencio, M.

doi:10.1016/j.jtho.2022.07.106

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the NADIM trial ( 47 ), lower pretreatment ctDNA levels were associated with improved PFS and OS, while undetectable ctDNA after neoadjuvant therapy was associated with better PFS and OS. Similar results were also found in NADIM II study ( 48 ). Another proof was reported by the LCMC3 study ( 49 ), indicating that ctDNA could be a predictor of better pathologic response and longer survival.…”

Section: Potential Predictive Factors Of Neoadjuvant Immunotherapysupporting

confidence: 91%

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

Chau

Bai

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) are highly concerned in the treatment of non-small cell lung cancer (NSCLC), represented by inhibitors of programmed death protein 1 (PD-1) and its ligand (PD-L1), and inhibitors of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The introduction of immunotherapy in the treatment of perioperative NSCLC has improved the prognosis to a great extent, as demonstrated by several phase II and III clinical trials. The target population for immunotherapy in early-stage NSCLC is still under discussion, and the biomarkers for neoadjuvant immunotherapy population selection are the next pending problem. The predictive efficacy of many potential makers is still being explored, including PD-L1 expression levels, tumor mutation burden, circulating tumor DNA, components of the tumor microenvironment, and several clinical factors. We summarize key findings on the utility of ICIs in clinical trials of preoperative NSCLC patients and conclude analyses of relevant biomarkers to provide a better understanding of potentially predictive biomarkers in neoadjuvant immunotherapy.

show abstract

Section: Potential Predictive Factors Of Neoadjuvant Immunotherapysupporting

confidence: 91%

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

Chau

Bai

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In the NADIM study, which showed 69.8% (30/43) of ctDNA in pretreatment plasma samples, showed that a low baseline ctDNA level was an independent predictive factor for PFS and OS after neoadjuvant chemotherapy plus nivolumab (PFS: HR = 0.20, 95% CI: 0.06–0.63, p = 0.006; OS: HR = 0.07, 95% CI: 0.01–0.39, p = 0.002) [ 58 ]. In this study, patients also had low ctDNA levels at baseline had a significantly longer PFS and OS after neoadjuvant chemoimmunotherapy than those with high ctDNA levels [ 59 ]. These findings suggest the prognostic value of baseline ctDNA, which is consistent with other studies on advanced cancer treated with ICIs in which a correlation between pretreatment ctDNA and long‐term survival was observed [ 60 ].…”

Section: Predictive Biomarkers For Adjuvant and Neoadjuvant Immunothe...mentioning

confidence: 99%

Adjuvant and neo‐adjuvant immunotherapy in resectable non‐small cell lung cancer (NSCLC): Current status and perspectives

Zou

Hao

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

Surgery followed by adjuvant chemotherapy is the standard of care for selected patients with early‐stage or locally advanced non‐small cell lung cancer (NSCLC). However, many of these patients still experience postoperative recurrence at 5 years. At present, peri‐operative treatment methods are emerging to prevent early relapse, such as targeted therapy and immunotherapy. Investigation on predictive biomarkers of responses to adjuvant and neoadjuvant therapies is also continuously ongoing. Immunotherapy represented by immune checkpoint inhibitors (ICIs), either by monotherapy or in combination with chemotherapy, has shown benefit in promoting pathological responses and prolonging survival for patients with NSCLC without oncogenic mutations. Exploratory studies have also provided evidence regarding the selection of patients who benefit from ICI‐based perioperative treatment. This review focuses on the existing data of current clinical trials of adjuvant and neoadjuvant strategies with ICIs in resectable NSCLC, the exploration of predictive biomarkers, and the perspectives and urgent challenges in the future.

show abstract

Treatment patterns and clinical outcomes of patients with resectable non–small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World)

Yang,

Wang,

Yang

et al. 2024

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

Cited by 3 publications

References 0 publications

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

Adjuvant and neo‐adjuvant immunotherapy in resectable non‐small cell lung cancer (NSCLC): Current status and perspectives

Treatment patterns and clinical outcomes of patients with resectable non–small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World)

Contact Info

Product

Resources

About